$ALZN
Alzamend Neuro, Inc. Stock $alzn

$alzn Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000121465923010076 Filed on July 27, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.160M	$1.657M	$7.425M
YoY Change	-30.1%	-25.08%	4.3%
% of Gross Profit
Research & Development	$2.366M	$1.648M	$7.446M
YoY Change	71.96%	-0.79%	43.15%
% of Gross Profit
Depreciation & Amortization	$12.69K	$5.330K	$23.07K
YoY Change	78.74%	50.14%	550.04%
% of Gross Profit
Operating Expenses	$3.526M	$3.305M	$14.87M
YoY Change	156.25%	-14.66%	185.9%
Operating Profit	-$3.526M		-$14.87M
YoY Change	16.15%		20.71%
Interest Expense	$1.835K	-$520.00	-$7.700K
YoY Change	19.78%	-13.33%	-116.55%
% of Operating Profit
Other Income/Expense, Net	-$1.835K		-$7.701K
YoY Change	19.78%		-81.89%
Pretax Income	-$3.530M	-$3.306M	-$14.88M
YoY Change	16.23%	-14.57%	20.35%
Income Tax
% Of Pretax Income
Net Earnings	-$3.528M	-$3.306M	-$14.88M
YoY Change	16.16%	-14.57%	20.35%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04		-$0.15
Diluted Earnings Per Share	-$0.04	-$0.03	-$0.15
COMMON SHARES
Basic Shares Outstanding	96.94M shares		97.52M shares
Diluted Shares Outstanding	98.44M shares		97.52M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.700M	$5.141M	$5.141M
YoY Change	-85.25%	-63.45%	-63.45%
Cash & Equivalents	$1.695M	$5.141M
Short-Term Investments
Other Short-Term Assets	$720.0K	$694.9K	$694.9K
YoY Change	24.54%	98.71%	98.71%
Inventory
Prepaid Expenses		$247.3K
Receivables
Other Receivables
Total Short-Term Assets	$2.414M	$5.836M	$5.836M
YoY Change	-80.08%	-59.51%	-59.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$214.4K	$79.84K	$79.84K
YoY Change	123.77%	-22.42%	-22.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$214.4K	$79.85K	$79.85K
YoY Change	123.77%	-22.41%	-22.41%
TOTAL ASSETS
Total Short-Term Assets	$2.414M	$5.836M	$5.836M
Total Long-Term Assets	$214.4K	$79.85K	$79.85K
Total Assets	$2.628M	$5.916M	$5.916M
YoY Change	-78.48%	-59.25%	-59.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.741M	$2.870M	$2.870M
YoY Change	166.44%	146.82%	146.82%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.740M	$2.870M	$2.870M
YoY Change	166.36%	146.38%	146.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.740M	$2.870M	$2.870M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.741M	$2.870M	$2.870M
YoY Change	166.44%	146.38%	146.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$47.60M	-$44.07M
YoY Change	47.68%	50.96%
Common Stock	$9.694K	$9.694K
YoY Change	1.53%	1.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$112.9K	$3.046M	$3.046M
YoY Change
Total Liabilities & Shareholders Equity	$2.628M	$5.916M	$5.916M
YoY Change	-78.48%	-59.25%	-59.25%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$3.528M	-$3.306M	-$14.88M
YoY Change	16.16%	-14.57%	20.35%
Depreciation, Depletion And Amortization	$12.69K	$5.330K	$23.07K
YoY Change	78.74%	50.14%	550.04%
Cash From Operating Activities	-$3.298M	-$2.235M	-$8.923M
YoY Change	30.02%	43.07%	34.91%
INVESTING ACTIVITIES
Capital Expenditures	$150.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$147.2K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$200.00	$200.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		200.0	200.0
YoY Change		-99.99%	-100.0%
NET CHANGE
Cash From Operating Activities	-$3.298M	-2.235M	-8.923M
Cash From Investing Activities	-$147.2K	0.000	0.000
Cash From Financing Activities		200.0	200.0
Net Change In Cash	-$3.445M	-2.235M	-8.923M
YoY Change	35.82%	-198.3%	-173.53%
FREE CASH FLOW
Cash From Operating Activities	-$3.298M	-$2.235M	-$8.923M
Capital Expenditures	$150.0K	$0.00	$0.00
Free Cash Flow	-$3.448M	-$2.235M	-$8.923M
YoY Change		53.53%	37.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001677077
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2023Q2	alxneuro	Related Party Payable RelatedPartyPayable		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2023	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2023	alxneuro	Proceeds From Initial Public Offering Net Of Underwriters Discounts And Commissions And Issuance Costs ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts		usd
CY2023	alxneuro	Fair Value Of Warrants Issued In Connection With March2021 Securities Purchase Agreement Related Party FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty		usd
CY2023	alxneuro	Conversion Of Series Convertible Preferred Stock ConversionOfSeriesConvertiblePreferredStock		usd
CY2023	alxneuro	Issuance Of Common Stock On Conversion Of Note IssuanceOfCommonStockOnConversionOfNote		usd
CY2023	alxneuro	Fair Value Of Warrants Issued In Connection With Initial Public Offering FairValueOfWarrantsIssuedInConnectionWithInitialPublicOffering		usd
CY2022	alxneuro	Issuance Of Common Stock For Related Party Payables IssuanceOfCommonStockForRelatedPartyPayables		usd
CY2022Q2	alxneuro	Prepaid Clinical Trial Fees PrepaidClinicalTrialFees		usd
CY2023Q2	alxneuro	Prepaid Consulting Fees PrepaidConsultingFees		usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals		usd
CY2022Q2	alxneuro	Deferred Tax Assets Tax Deferred Expense Capitalized Research Expenditures DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchExpenditures		usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	alxneuro	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross		shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-04-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40483
CY2023	dei	Entity Registrant Name EntityRegistrantName	ALZAMEND NEURO, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-1822909
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3480 Peachtree Road NE
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Second Floor Suite 103
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Atlanta
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30326
CY2023	dei	City Area Code CityAreaCode	(844)
CY2023	dei	Local Phone Number LocalPhoneNumber	722-6333
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	ALZN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	66400000	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96940124	shares
CY2023	dei	Auditor Firm AuditorFirmId	23
CY2023	dei	Auditor Name AuditorName	BAKER TILLY US, LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5140859	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14063811	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	447589	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	349723	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	247334	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	5835782	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	14413534	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79843	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	102909	usd
CY2023Q2	us-gaap	Assets Assets	5915625	usd
CY2022Q2	us-gaap	Assets Assets	14516443	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2870122	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1162850	usd
CY2022Q2	alxneuro	Related Party Payable RelatedPartyPayable	2082	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2870122	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1164932	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2870122	usd
CY2022Q2	us-gaap	Liabilities Liabilities	1164932	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96940124	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96940124	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95481790	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95481790	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	9694	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	9548	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61991766	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57419753	usd
CY2023Q2	alxneuro	Note Receivable For Common Stock Related Party NoteReceivableForCommonStockRelatedParty	-14883295	usd
CY2022Q2	alxneuro	Note Receivable For Common Stock Related Party NoteReceivableForCommonStockRelatedParty	-14883295	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44072662	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29194495	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3045503	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	13351511	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5915625	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14516443	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7445857	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5201314	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7424609	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7118221	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	14870466	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	12319535	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-14870466	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-12319535	usd
CY2023	us-gaap	Interest Expense InterestExpense	7701	usd
CY2022	us-gaap	Interest Expense InterestExpense	46524	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	4000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7701	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-42524	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14878167	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12362059	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97519016	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97519016	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89095274	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89095274	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2012947	usd
CY2022	alxneuro	Stockbased Compensation To Employees And Consultants StockbasedCompensationToEmployeesAndConsultants	4408569	usd
CY2022	alxneuro	Proceeds From Sale Of Common Stocks Warrantsrelated Party ProceedsFromSaleOfCommonStocksWarrantsrelatedParty	6000000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2200	usd
CY2022	alxneuro	Proceeds From Initial Public Offering Net Of Underwriters Discounts And Commissions And Issuance Costs Of1.5 Million ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCostsOf1.5Million	12911456	usd
CY2022	alxneuro	Issuance Of Shares Of Common Stock For Conversion Of Debt IssuanceOfSharesOfCommonStockForConversionOfDebt	378398	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12362059	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	13351511	usd
CY2023	alxneuro	Stockbased Compensation To Employees And Consultants StockbasedCompensationToEmployeesAndConsultants	3582625	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	200	usd
CY2023	alxneuro	Issuance Of Common Stock For Related Party Payable IssuanceOfCommonStockForRelatedPartyPayable	989334	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14878167	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3045503	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14878167	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12362059	usd
CY2023	us-gaap	Depreciation Depreciation	23066	usd
CY2022	us-gaap	Depreciation Depreciation	3549	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	12770	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	4000	usd
CY2023	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	8900000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3582625	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4408569	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	97866	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-633597	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-739918	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1707272	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	693584	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8923152	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6613990	usd
CY2022	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	106458	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-106458	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6000000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2200	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	58667	usd
CY2022	alxneuro	Proceeds From Initial Public Offering Net Of Underwriters Discounts And Commissions And Issuance Costs ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts	12911456	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18854989	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8922952	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	12134541	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14063811	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1929270	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5140859	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14063811	usd
CY2022	alxneuro	Fair Value Of Warrants Issued In Connection With March2021 Securities Purchase Agreement Related Party FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty	5374509	usd
CY2022	alxneuro	Conversion Of Series Convertible Preferred Stock ConversionOfSeriesConvertiblePreferredStock	1425	usd
CY2022	alxneuro	Issuance Of Common Stock On Conversion Of Note IssuanceOfCommonStockOnConversionOfNote	378398	usd
CY2022	alxneuro	Fair Value Of Warrants Issued In Connection With Initial Public Offering FairValueOfWarrantsIssuedInConnectionWithInitialPublicOffering	194490	usd
CY2023	alxneuro	Issuance Of Common Stock For Related Party Payables IssuanceOfCommonStockForRelatedPartyPayables	989334	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Cash Cash	5100000	usd
CY2023Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	44100000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	14900000	usd
CY2022Q2	us-gaap	Cash Cash	14100000	usd
CY2022Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	29200000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zVcSzJPtN1Q" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_z2WVTYJnxuF4">Accounting Estimates</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include research and development, stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p>
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28358117	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28824788	shares
CY2023	alxneuro	Long Term Debt Average Amount Of Outstanding LongTermDebtAverageAmountOfOutstanding	14883295	usd
CY2022	alxneuro	Long Term Debt Average Amount Of Outstanding LongTermDebtAverageAmountOfOutstanding	14883295	usd
CY2023Q2	alxneuro	Prepaid Clinical Trial Fees PrepaidClinicalTrialFees	352635	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	92154	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	155880	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2800	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7176	usd
CY2022Q2	alxneuro	Prepaid Consulting Fees PrepaidConsultingFees	186667	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	447589	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	349723	usd
CY2022Q2	alxneuro	Purchase Director And Officer Insurance PurchaseDirectorAndOfficerInsurance	492000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-14878167	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12362059	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14878167	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12362059	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	241500	usd
CY2023Q2	alxneuro	Deferred Tax Assets Tax Deferred Expense Capitalized Research Expenditures DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchExpenditures	1426779	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6885428	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8376539	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2276109	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1722003	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10829816	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10098542	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	16767	usd
CY2022Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	21611	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10813049	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10076931	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.183	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.123	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.048	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.463	pure
CY2023	alxneuro	Stock Compensation Rate StockCompensationRate	0.003	pure
CY2022	alxneuro	Stock Compensation Rate StockCompensationRate	0.130	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.020	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.000	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10813049	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10076931	usd
CY2023Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	8800000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15700000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.2154
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2219700	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2000000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2000000
CY2023	alxneuro	Share Based Compensation Arrangements By Share Based Payment Award Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageExercisePrice	1.1700
CY2023	alxneuro	Weighted Average Remaining Contractual Life Option Granted WeightedAverageRemainingContractualLifeOptionGranted	P9Y6M29D
CY2023	alxneuro	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Options Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForOptionsExercised	-500000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.0004
CY2023	alxneuro	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Cancelled Or Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited	2391671	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2391671	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.3415
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	9191671	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14808329	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.2154
CY2023	alxneuro	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y2M4D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	819900	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13808329	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.2187
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y11M4D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	819900	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	13036969	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.1784
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M25D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	995400	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3582625	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4408569	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10149788	shares
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y10M24D
CY2023Q2	alxneuro	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	2.90
CY2023Q2	alxneuro	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	10149788	shares
CY2023Q2	alxneuro	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	2.90
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2875000	usd
CY2021Q2	us-gaap	Demutualization By Insurance Entity Securities Issued Price Per Share Or Unit DemutualizationByInsuranceEntitySecuritiesIssuedPricePerShareOrUnit	5.00
CY2021Q2	us-gaap	Demutualization By Insurance Entity Securities Issued Gross Cash Proceeds DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds	14400000	usd
CY2021Q2	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	12900000	usd

Files In Submission

Name	View Source	Status
0001214659-23-010076-index-headers.html	Edgar Link	pending
0001214659-23-010076-index.html	Edgar Link	pending
0001214659-23-010076.txt	Edgar Link	pending
0001214659-23-010076-xbrl.zip	Edgar Link	pending
al71823010k.htm	Edgar Link	pending
alxneuro-20230430.xsd	Edgar Link	pending
devpipeline.jpg	Edgar Link	pending
ex10_13.htm	Edgar Link	pending
alxneuro-20230430_cal.xml	Edgar Link	unprocessable
alxneuro-20230430_def.xml	Edgar Link	unprocessable
alxneuro-20230430_lab.xml	Edgar Link	unprocessable
alxneuro-20230430_pre.xml	Edgar Link	unprocessable
al71823010k_htm.xml	Edgar Link	completed
ex10_14.htm	Edgar Link	pending
ex10_15.htm	Edgar Link	pending
ex10_16.htm	Edgar Link	pending
ex10_17.htm	Edgar Link	pending
ex23_1.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
landscape.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
popluationchart.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALZN
Alzamend Neuro, Inc. Stock $alzn

2023 Q3 Form 10-K Financial Statement

#000121465923010076 Filed on July 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALZN Alzamend Neuro, Inc. Stock $alzn

2023 Q3 Form 10-K Financial Statement

#000121465923010076 Filed on July 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALZN
Alzamend Neuro, Inc. Stock $alzn